[ABBV] AbbVie Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 62.32 Change: 0.67 (1.08%)
Ext. hours: 62.4 Change: 0.08 (0.13%)

chart ABBV

Refresh chart

Strongest Trends Summary For ABBV

ABBV is in the long-term up 65% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated

Fundamental Ratios
Shares Outstanding EPS4 EPS Growth - 4 Quarters-44.47% EPS Growth - Q/Q-115.9%
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.31% Sales Growth - Q/Q-7.56% P/E17.76
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.8% ROE131.88% ROI11.6%
Current Ratio1.39 Quick Ratio1.3 Long Term Debt/Equity2.45 Debt Ratio8.02
Gross Margin79.12% Operating Margin18.33% Net Profit Margin8.89% Dividend Payout Ratio-154.52%
Dividend Yield
Fundamental Data
Cash From Financing Activities-930 M Cash From Investing Activities-873 M Cash From Operating Activities1.59 B Gross Profit4.58 B
Net Profit1.37 B Operating Profit2.11 B Total Assets26.7 B Total Current Assets15.41 B
Total Current Liabilities11.05 B Total Debt15.27 B Total Liabilities25.32 B Total Revenue5.48 B
Technical Data
High 52 week121.94 Low 52 week64.52 Last close99.98 Last change0.75%
RSI36.24 Average true range2.28 Beta1.14 Volume4.37 M
Simple moving average 20 days-2.68% Simple moving average 50 days2.42% Simple moving average 200 days2.97%
Performance Data
Performance Week-2.94% Performance Month0.35% Performance Quart-11.94% Performance Half6.85%
Performance Year50.73% Performance Year-to-date5.21% Volatility daily1.66% Volatility weekly3.7%
Volatility monthly7.59% Volatility yearly26.29% Relative Volume229.33% Average Volume8.94 M
New High New Low


2019-03-26 01:00:00 | AbbVie Announces First Regulatory Approval of SKYRIZI™ risankizumab for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

2019-03-25 17:45:09 | AbbVie ABBV Dips More Than Broader Markets: What You Should Know

2019-03-24 18:33:00 | 4 Blockbuster Drug Launches to Watch in 2019

2019-03-24 14:00:00 | 3 Bargain Stocks You Can Buy Today

2019-03-24 09:07:00 | Where Will AbbVie Be in 10 Years?

2019-03-22 09:15:01 | This is Why AbbVie ABBV is a Great Dividend Stock

2019-03-21 20:00:00 | Better Buy: AbbVie vs. Eli Lilly

2019-03-21 07:56:26 | Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons

2019-03-20 11:10:03 | AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

2019-03-19 10:21:36 | Why You Should Buy ABBV Stock for Income and Value

2019-03-19 09:36:29 | FDA puts partial hold on clinical trials of AbbVie's cancer drug

2019-03-19 09:07:00 | AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma

2019-03-19 08:45:00 | AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® venetoclax Multiple Myeloma Program

2019-03-18 17:45:09 | AbbVie ABBV Stock Sinks As Market Gains: What You Should Know

2019-03-18 13:36:00 | Big Pharma Earnings Might Not Be as Good as They Look

2019-03-17 09:03:00 | 2 Things Investors Are Missing About AbbVie

2019-03-14 10:36:02 | Roche Receives EC Approval for Label Expansion of Hemlibra

2019-03-14 09:14:00 | 3 Dividend Aristocrats to Buy and Hold Forever

2019-03-14 06:00:00 | The Timely Ten- Blue Chip Buys with Value and Yield

2019-03-14 05:01:25 | Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades

2019-03-13 14:27:06 | Theravance TBPH Starts Dosing in Ulcerative Colitis Study

2019-03-13 08:37:57 | FDA medical adviser: 'Congress is owned by pharma'

2019-03-12 17:07:13 | Takeda's Entyvio Tops AbbVie's Humira in Patients With Ulcerative Colitis

2019-03-12 10:50:02 | Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

2019-03-12 10:27:51 | See what the IHS Markit Score report has to say about AbbVie Inc.

2019-03-11 17:45:09 | AbbVie ABBV Gains But Lags Market: What You Should Know

2019-03-11 11:05:03 | Should Value Investors Consider Abbvie ABBV Stock Now?

2019-03-10 10:36:18 | 10 Stocks For The Gene Therapy Revolution

2019-03-10 09:00:00 | 4 Stocks to Buy With Dividends Yielding More Than 4%

2019-03-08 13:45:06 | Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

2019-03-08 10:20:28 | Don’t Abandon Gilead Stock After Weak Q4 Results

2019-03-08 09:35:02 | Roche's RHHBY Tecentriq Gets EC Nod for First-Line NSCLC

2019-03-07 15:32:38 | The Kiplinger Dividend 15 Is On a Roll

2019-03-07 10:35:00 | UPDATE: Bio-Path stock gains another 130% on Thursday

2019-03-07 08:46:00 | AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients

2019-03-07 08:40:01 | Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

2019-03-07 06:03:00 | 2 Biotech Stocks With Major Incoming Catalysts

2019-03-06 14:30:00 | Bio-Path stock soars in active trade after announcing Phase 2 trial update

2019-03-06 13:32:39 | 7 Stocks That Can Outperform In a Post QE Market

2019-03-06 09:15:02 | Are You Looking for a High-Growth Dividend Stock? AbbVie ABBV Could Be a Great Choice

2019-03-06 07:30:02 | What Are Mylan’s Key Growth Drivers in Fiscal 2019?

2019-03-05 09:51:02 | The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy

2019-03-04 15:27:08 | Top Research Reports for Intel, AbbVie & United Technologies

2019-03-04 10:05:03 | AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

2019-03-01 09:29:02 | Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices

2019-03-01 08:00:00 | AbbVie to Present at the Barclays Global Healthcare Conference

2019-03-01 07:00:00 | AbbVie Receives CHMP Positive Opinion for Risankizumab SKYRIZI™ for the Treatment of Moderate to Severe Plaque Psoriasis

2019-02-28 14:44:21 | These 10 New Drugs Expected In 2019 Are On The Blockbuster Track

2019-02-28 14:16:05 | Is now the time to buy Rio Tinto? How does Abbvie look here? The desk answers your questions

2019-02-28 11:24:00 | 3 Top Stocks With High Dividend Yields